• Telix reported completion of patient enrollment in its Phase 1 IPAX-2 study of TLX101-Tx in newly diagnosed glioblastoma, with dosing now confirmed.
• Results have not been presented; the study will confirm its primary dosing endpoint at completion while patients continue standard treatment.
• The trial has so far shown the treatment was tolerated with no dose-limiting safety issues observed, supporting continued development in the first-line setting.
• TLX101-Tx is also being tested in the Phase 3 IPAX BrIGHT trial in recurrent glioblastoma, which is enrolling and dosing patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.